Literature DB >> 10505630

Neuronal intranuclear inclusions in spinocerebellar ataxia type 2: triple-labeling immunofluorescent study.

S Koyano1, T Uchihara, H Fujigasaki, A Nakamura, S Yagishita, K Iwabuchi.   

Abstract

Spinocerebellar ataxia type 2 (SCA2) is associated with an expansion of CAG/polyglutamine-repeat of a gene of unknown function. We performed an immunohistochemical study to identify the immunolocalization of the disease protein ataxin-2 in normal and SCA2 patients. Although normal and expanded ataxin-2 were ubiquitously localized to the cytoplasm of neurons, ubiquitinated intranuclear inclusions were observed selectively in 1-2% of neurons of affected brain regions except the cerebellum. Triple-labeling immunofluorescence revealed that ataxin-2, expanded polyglutamine and ubiquitin were colocalized to these neuronal intranuclear inclusions (NIs), indicating that SCA2 shares morphological characteristics common to other neurological disorders associated with an expansion of CAG/polyglutamine-repeat. Lack of NIs in the cerebellar lesion, however, suggests the discrepancy between formation of NIs and neuronal degeneration in SCA2.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10505630     DOI: 10.1016/s0304-3940(99)00656-4

Source DB:  PubMed          Journal:  Neurosci Lett        ISSN: 0304-3940            Impact factor:   3.046


  25 in total

Review 1.  Aggregation formation in the polyglutamine diseases: protection at a cost?

Authors:  Tiffany W Todd; Janghoo Lim
Journal:  Mol Cells       Date:  2013-06-19       Impact factor: 5.034

2.  Frontotemporal cognitive function in X-linked spinal and bulbar muscular atrophy (SBMA): a controlled neuropsychological study of 20 patients.

Authors:  Georg Rüdiger Soukup; Anne-Dorte Sperfeld; Ingo Uttner; Jochen Karitzky; Albert Christian Ludolph; Jan Kassubek; Herbert Schreiber
Journal:  J Neurol       Date:  2009-07-02       Impact factor: 4.849

3.  Interaction between neuronal intranuclear inclusions and promyelocytic leukemia protein nuclear and coiled bodies in CAG repeat diseases.

Authors:  M Yamada; T Sato; T Shimohata; S Hayashi; S Igarashi; S Tsuji; H Takahashi
Journal:  Am J Pathol       Date:  2001-11       Impact factor: 4.307

Review 4.  Spinocerebellar ataxia type 2: clinical presentation, molecular mechanisms, and therapeutic perspectives.

Authors:  J J Magaña; L Velázquez-Pérez; B Cisneros
Journal:  Mol Neurobiol       Date:  2012-09-21       Impact factor: 5.590

5.  Intracellular green fluorescent protein-polyalanine aggregates are associated with cell death.

Authors:  J Rankin; A Wyttenbach; D C Rubinsztein
Journal:  Biochem J       Date:  2000-05-15       Impact factor: 3.857

6.  Bacterial and yeast chaperones reduce both aggregate formation and cell death in mammalian cell models of Huntington's disease.

Authors:  J Carmichael; J Chatellier; A Woolfson; C Milstein; A R Fersht; D C Rubinsztein
Journal:  Proc Natl Acad Sci U S A       Date:  2000-08-15       Impact factor: 11.205

Review 7.  The roles of proteolysis and nuclear localisation in the toxicity of the polyglutamine diseases. A review.

Authors:  R Walsh; E Storey; D Stefani; L Kelly; V Turnbull
Journal:  Neurotox Res       Date:  2005       Impact factor: 3.911

Review 8.  Studying polyglutamine diseases in Drosophila.

Authors:  Zhen Xu; Antonio Joel Tito; Yan-Ning Rui; Sheng Zhang
Journal:  Exp Neurol       Date:  2015-08-06       Impact factor: 5.330

9.  Characterization of intracellular aggregates using fluorescently-tagged polyglutamine-expanded androgen receptor.

Authors:  V Panet-Raymond; B Gottlieb; L K Beitel; H Schipper; M Timiansky; L Pinsky; M A Trifiro
Journal:  Neurotox Res       Date:  2001-07       Impact factor: 3.911

10.  Ataxin-2 interacts with the DEAD/H-box RNA helicase DDX6 and interferes with P-bodies and stress granules.

Authors:  Ute Nonhoff; Markus Ralser; Franziska Welzel; Ilaria Piccini; Daniela Balzereit; Marie-Laure Yaspo; Hans Lehrach; Sylvia Krobitsch
Journal:  Mol Biol Cell       Date:  2007-02-07       Impact factor: 4.138

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.